Extensions

For US patent 12576080, here is a detailed breakdown of its term adjustments, extensions, related applications, and projected expiration date:

Continuation and Divisional Applications; Related Family Members

US patent 12576080 is part of an extensive patent family, claiming benefit as a continuation application from several prior applications and ultimately tracing priority back to provisional applications. There are no explicit mentions of "divisional applications" in the provided text, but the patent details a chain of continuation applications.

The lineage of US12576080, as stated in its "CROSS-REFERENCE" section, is as follows:

• This application (US12576080) is a continuation of U.S. patent application Ser. No. 18/423,908, filed Jan. 26, 2024.
• Which is a continuation of U.S. patent application Ser. No. 17/543,505, filed Dec. 6, 2021, now issued as U.S. Pat. No. 11,903,941.
• Which is a continuation of U.S. patent application Ser. No. 16/566,237, filed Sep. 10, 2019, now issued as U.S. Pat. No. 11,224,598.
• Which is a continuation of U.S. patent application Ser. No. 15/422,382, filed Feb. 1, 2017, now issued as U.S. Pat. No. 10,456,396.
• Which is a continuation of U.S. patent application Ser. No. 14/887,248, filed Oct. 19, 2015, now issued as U.S. Pat. No. 9,597,284.
• The earliest applications from which benefit is claimed are U.S. Provisional Application No. 62/066,280, filed Oct. 20, 2014, and U.S. Provisional Application No. 62/100,844, filed Jan. 7, 2015.

The priority date for US12576080 is October 20, 2014 [cite: Prior art date 2014-10-20, Priority date 2014-10-20].

Patent Term Adjustments (PTA)

Patent Term Adjustment (PTA) is granted to utility or plant patents to compensate for certain administrative delays by the U.S. Patent and Trademark Office (USPTO) during the patent prosecution process. These delays include the USPTO failing to:

• Issue a first office action within 14 months of filing.
• Respond to applicant replies or appeals within four months.
• Issue a patent within four months after payment of the issue fee.
• Issue a patent within 36 months from the application's filing date ("B" delay).

The total PTA calculation is determined by a computer program at the time of patent issuance and is typically included in the Issue Notification Letter. While the concept of PTA is applicable to US12576080 as a utility patent, the specific amount of PTA awarded for this patent is not directly provided in the authoritative text or readily available through general searches for the patent number itself. To ascertain the exact PTA, one would typically need to consult the official file wrapper or the issued patent document from the USPTO Patent Center.

Patent Term Extensions (PTE)

Patent Term Extension (PTE) may be granted for patents on certain human drugs, food or color additives, medical devices, animal drugs, and veterinary biological products to restore a portion of the patent term lost due to premarket government regulatory review periods, primarily by the FDA. A PTE application must be filed within 60 days of the product's commercial marketing or use approval by the FDA, and the extension can be for up to five years, with the total patent term (including PTE) limited to fourteen years from the date of product approval.

As of the current date, direct search results for US12576080 do not indicate that a Patent Term Extension (PTE) has been applied for or granted. Given that Oyster Point Pharma Inc. developed TYRVAYA® (varenicline solution) nasal spray, which treats dry eye disease and aligns with the patent's subject matter, it is plausible that a PTE could be sought if the patent covers an FDA-approved product. However, without official USPTO records specifically listing a PTE for US12576080, its presence cannot be confirmed with high confidence.

Projected Expiration Date

Based on the general information provided for US12576080, the anticipated expiration date is 2035-10-19 [cite: Anticipated expiration 2035-10-19]. This date is typically calculated as 20 years from the earliest priority date (October 20, 2014 [cite: Priority date 2014-10-20]), plus any awarded Patent Term Adjustment (PTA), and potentially Patent Term Extension (PTE) if applicable. Without the specific PTA and PTE figures, this provided date serves as the current best estimate.